Xanthomas Follow-up

  • Author: Kevaghn P Fair, DO; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Jan 24, 2012
 

Patient Education

 
Contributor Information and Disclosures
Author

Kevaghn P Fair, DO  Consultant Pathologist and Founder, Dominion Pathology Laboratories

Kevaghn P Fair, DO is a member of the following medical societies: American Society for Clinical Pathology, American Society of Dermatopathology, and College of American Pathologists

Disclosure: Nothing to disclose.

Specialty Editor Board

Ponciano D Cruz Jr, MD  Vice-Chair, JB Shelmire Professor, Department of Dermatology, University of Texas Southwestern Medical Center

Ponciano D Cruz Jr, MD is a member of the following medical societies: Texas Medical Association

Disclosure: RCTS Consulting fee Independent contractor; Mary Kay Cosmetics Honoraria Consulting; Galderma Grant/research funds Principal Investigator

Michael J Wells, MD  Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Edward F Chan, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Edward F Chan, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. Sharma D, Thirkannad S. Palmar Xanthoma-An Indicator of a More Sinister Problem. Hand (N Y). Sep 22 2009;[Medline].

  2. Huijgen R, Stork A, Defesche J, Peter J, Alonso R, Cuevas A, et al. Extreme xanthomatosis in patients with both familial hypercholesterolemia and cerebrotendinous xanthomatosis. Clin Genet. Jan 2012;81(1):24-8. [Medline].

  3. Streit E, Helmbold P. [65-year-old man with yellow-orange papules on both forearms. Eruptive xanthomas]. Hautarzt. Oct 2009;60(10):834-7. [Medline].

  4. Rosmaninho A, Fernandes I, Guimas A, Amorim I, Selores M. Diffuse plane xanthomatosis associated with monoclonal gammopathy. An Bras Dermatol. Jul-Aug 2011;86(4 Suppl 1):S50-2. [Medline].

  5. Szalat R, Arnulf B, Karlin L, Rybojad M, Asli B, Malphettes M, et al. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. Blood. Oct 6 2011;118(14):3777-84. [Medline].

  6. Caputo R, Monti M, Berti E, Gasparini G. Normolipemic eruptive cutaneous xanthomatosis. Arch Dermatol. Nov 1986;122(11):1294-7. [Medline].

  7. Inazu A, Koizumi J, Kajinami K, Kiyohar T, Chichibu K, Mabuchi H. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. Atherosclerosis. Aug 1999;145(2):405-13. [Medline].

  8. Fujita M, Shirai K. A comparative study of the therapeutic effect of probucol and pravastatin on xanthelasma. J Dermatol. Sep 1996;23(9):598-602. [Medline].

  9. Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol. Jun 27 1986;57(16):29H-35H. [Medline].

  10. Kuo PT, Hayase K, Kostis JB, Moreyra AE. Use of combined diet and colestipol in long-term (7--7 1/2 years) treatment of patients with type II hyperlipoproteinemia. Circulation. Feb 1979;59(2):199-211. [Medline].

  11. Mendelson BC, Masson JK. Xanthelasma: follow-up on results after surgical excision. Plast Reconstr Surg. Nov 1976;58(5):535-8. [Medline].

  12. Raulin C, Schoenermark MP, Werner S, Greve B. Xanthelasma palpebrarum: treatment with the ultrapulsed CO2 laser. Lasers Surg Med. 1999;24(2):122-7. [Medline].

  13. Borelli C, Kaudewitz P. Xanthelasma palpebrarum: treatment with the erbium:YAG laser. Lasers Surg Med. 2001;29(3):260-4. [Medline].

  14. Basar E, Oguz H, Ozdemir H, Ozkan S, Uslu H. Treatment of xanthelasma palpebrarum with argon laser photocoagulation. Argon laser and xanthelasma palpebrarum. Int Ophthalmol. Jan 2004;25(1):9-11. [Medline].

  15. Haygood LJ, Bennett JD, Brodell RT. Treatment of xanthelasma palpebrarum with bichloracetic acid. Dermatol Surg. Sep 1998;24(9):1027-31. [Medline].

  16. Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol. Nov 5 1998;82(9A):3Q-12Q. [Medline].

  17. Cruz PD Jr, East C, Bergstresser PR. Dermal, subcutaneous, and tendon xanthomas: diagnostic markers for specific lipoprotein disorders. J Am Acad Dermatol. Jul 1988;19(1 Pt 1):95-111. [Medline].

  18. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med. Jan 5 1967;276(1):34-42 contd. [Medline].

  19. Goldstein JL, Brown MS. Familial hypercholesterolemia. A genetic regulatory defect in cholesterol metabolism. Am J Med. Feb 1975;58(2):147-50. [Medline].

  20. Haber C, Kwiterovich PO Jr. Dyslipoproteinemia and xanthomatosis. Pediatr Dermatol. Apr 1984;1(4):261-80. [Medline].

  21. Havel RJ. Approach to the patient with hyperlipidemia. Med Clin North Am. Mar 1982;66(2):319-33. [Medline].

  22. Hu CH, Ellefson RD, Winkelmann RK. Lipid synthesis in cutaneous xanthoma. J Invest Dermatol. Aug 1982;79(2):80-5. [Medline].

  23. Parker F. Xanthomas and hyperlipidemias. J Am Acad Dermatol. Jul 1985;13(1):1-30. [Medline].

  24. Rader DJ. Pathophysiology and management of low high-density lipoprotein cholesterol. Am J Cardiol. May 13 1999;83(9B):22F-24F. [Medline].

  25. Vermeer BJ, Gevers Leuven J. New aspects of xanthomatosis and hyperlipoproteinemia. Curr Probl Dermatol. 1991;20:63-72. [Medline].

 
Previous
Next
 
Xanthelasma. Courtesy of Duke University Medical Center.
Eruptive xanthomas. Courtesy of Duke University Medical Center.
Tuberous xanthomas. Courtesy of Duke University Medical Center.
Microscopic image of a xanthelasma. The lesion is composed of lipid-laden macrophages located in the superficial dermis. Courtesy of Duke University Medical Center.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.